ESR1 and breast carcinoma: This time, CausalPath results were not significant in terms of the overall network size (p = 0.2218); nevertheless, they indicate that ESR1 is significantly more active in luminal breast cancers, suggested by both its protein levels and the changes in its downstream (Figure 4C).